Adam Crystal Sells 27,000 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Adam Crystal sold 27,000 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $21.23, for a total transaction of $573,210.00. Following the sale, the insider owned 115,743 shares of the company’s stock, valued at approximately $2,457,223.89. This represents a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Adam Crystal also recently made the following trade(s):

• On Wednesday, April 15th, Adam Crystal sold 38,460 shares of Tango Therapeutics stock. The stock was sold at an average price of $25.00, for a total value of $961,500.00.
• On Wednesday, April 1st, Adam Crystal sold 27,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $21.20, for a total value of $572,400.00.
• On Wednesday, March 25th, Adam Crystal sold 12,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $20.11, for a total value of $241,320.00.
• On Thursday, March 5th, Adam Crystal sold 20,251 shares of Tango Therapeutics stock. The stock was sold at an average price of $15.00, for a total value of $303,765.00.
• On Wednesday, February 25th, Adam Crystal sold 54,345 shares of Tango Therapeutics stock. The stock was sold at an average price of $12.77, for a total value of $693,985.65.

Tango Therapeutics Stock Performance

TNGX opened at $23.62 on Thursday. The stock has a market capitalization of $3.41 billion, a PE ratio of -27.15 and a beta of 1.22. The stock’s 50 day moving average price is $19.96 and its 200-day moving average price is $13.54. Tango Therapeutics, Inc. has a 52-week low of $1.03 and a 52-week high of $28.41.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02. Tango Therapeutics had a negative return on equity of 50.30% and a negative net margin of 151.15%. Research analysts forecast that Tango Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Tango Therapeutics

Hedge funds have recently bought and sold shares of the business. Global Retirement Partners LLC bought a new position in shares of Tango Therapeutics during the fourth quarter valued at approximately $35,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Tango Therapeutics by 148,800.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock worth $40,000 after purchasing an additional 4,464 shares in the last quarter. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Tango Therapeutics in the 4th quarter worth approximately $40,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Tango Therapeutics by 52.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock worth $58,000 after buying an additional 2,243 shares during the last quarter. Finally, Legal & General Group Plc increased its position in Tango Therapeutics by 30.7% during the 2nd quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock valued at $36,000 after buying an additional 1,640 shares in the last quarter. Institutional investors own 78.99% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Guggenheim boosted their price target on shares of Tango Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Mizuho raised their price objective on shares of Tango Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Wednesday, March 11th. B. Riley Financial reaffirmed a “buy” rating on shares of Tango Therapeutics in a research report on Friday, March 27th. Piper Sandler upped their target price on Tango Therapeutics from $11.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, January 16th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $18.00 target price on shares of Tango Therapeutics in a research report on Thursday, March 5th. Eleven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Tango Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.44.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.